Is a Universal Influenza Virus Vaccine Possible?

  title={Is a Universal Influenza Virus Vaccine Possible?},
  author={Raffael Nachbagauer and Peter Palese},
  journal={Annual review of medicine},
Influenza viruses remain a severe burden to human health because of their contribution to overall morbidity and mortality. Current seasonal influenza virus vaccines do not provide sufficient protection to alleviate the annual impact of influenza and cannot confer protection against potentially pandemic influenza viruses. The lack of protection is due to rapid changes of the viral epitopes targeted by the vaccine and the often suboptimal immunogenicity of current immunization strategies. Major… 
Tracking progress in universal influenza vaccine development.
This review highlights a new effort to track the development of universal influenza vaccine technologies and is intended to provide stakeholders and funders with a common source of information to monitor research progress and identify opportunities for informed investments and collaboration.
Toward a universal influenza virus vaccine: Some cytokines may fulfill the request.
Evaluation of the data obtained from this study showed that the DNA- vaccines coding NPm have more ability to induces a potent cross-cellular immune response and protective immunity than DNA-vaccines coding NP.
Host immune response–inspired development of the influenza vaccine
Influenza vaccine design can benefit from novel insights obtained from the study of host responses to influenza virus infection and vaccination that can elucidate novel correlates of protection and will guide further development of influenza vaccine.
Broadly Neutralizing Antibodies for Influenza: Passive Immunotherapy and Intranasal Vaccination
Two potentially valuable bnAbs for influenza are reviewed; one is a novel passive immunotherapy using a variable domain of heavy chain-only antibody (VHH), and the other is polymeric immunoglobulin A (pIgA) induced by intranasal vaccination.
New Points of Departure for More Global Influenza Vaccine Use
The challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic.
Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development
Proof-of-concept studies for the development of next-generation influenza vaccines using the bacteriophage T4 virus-like particle (VLP) platform are reported, demonstrating highly immunogenic M2e-decorated nanoparticles that stimulate robust humoral as well as cellular immune responses and conferred complete protection against lethal influenza virus challenge.
Bacteriophage T4 Vaccine Platform for Next-generation Influenza Vaccine Development
Proof-of-concept for the development of next-generation influenza vaccine using T4 phage virus-like particle (VLP) platform is provided and it is shown that more than 1,280 M2e molecules can be assembled on a 120×90 nanometer phage capsid to form T4-M2e VLPs, which are highly immunogenic and induced complete protection against influenza virus challenge without any addition adjuvant.
Influenza B virus strains are one of the components of seasonal influenza vaccines in both trivalent and quadrivalent formulations. The vast majority of these vaccines are produced in embryonated
Polyclonal epitope mapping reveals temporal dynamics and diversity of human antibody responses to H5N1 vaccination
EM polyclonal epitope mapping (EMPEM) provides a robust tool for comprehensively tracking the specificity and durability of immune responses elicited by novel universal influenza vaccine candidates.
Aggregation by peptide conjugation rescues poor immunogenicity of the HA stem
It is shown that a chemically coupling a peptide derived from the head domain of PR8 HA (P35) with the poorly immunogenic HA stem protein results in aggregation of the HA stem which significantly increases stem-specific B cell responses following vaccination.